1. |
Collins PJ, McMahon G, O’Brien P, et al. Purification, identification and characterisation of seprase from bovine serum. Int J Biochem Cell Biol, 2004, 36(11): 2320-2333.
|
2. |
Lee KN, Jackson KW, Christiansen VJ, et al. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood, 2006, 107(4): 1397-1404.
|
3. |
Tillmanns J, Fraccarollo D, Galuppo P, et al. Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI. Int J Cardiol, 2017, 232: 155-159.
|
4. |
Wild N, Andres H, Rollinger W, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res, 2010, 16(24): 6111-6121.
|
5. |
Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl, 2014, 8(5-6): 454-463.
|
6. |
Yamaguchi U, Honda K, Yamada T. Gene expression profiling of gastrointestinal stromal tumor: implications for clinical management. European J Clin Med Oncol, 2010, 2(2): 1-4.
|
7. |
Baerts L, Brouns R, Kehoe K, et al. Acute ischemic stroke severity, progression, and outcome relate to changes in dipeptidyl peptidase Ⅳ and fibroblast activation protein activity. Transl Stroke Res, 2017, 8(2): 157-164.
|
8. |
Busek P, Hrabal P, Fric P, et al. Co-expression of the homologous proteases fibroblast activation protein and dipeptidyl peptidase-Ⅳ in the adult human Langerhans islets. Histochem Cell Biol, 2015, 143(5): 497-504.
|
9. |
Keane FM, Nadvi NA, Yao TW, et al. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α. FEBS J, 2011, 278(8): 1316-1332.
|
10. |
Christiansen VJ, Jackson KW, Lee KN, et al. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types Ⅰ, Ⅲ, and Ⅳ. Arch Biochem Biophys, 2007, 457(2): 177-186.
|
11. |
Sánchez-Garrido MA, Habegger KM, Clemmensen C, et al. Fibroblast activation protein (FAP) as a novel metabolic target. Mol Metab, 2016, 5(10): 1015-1024.
|
12. |
Jiang GM, Xu W, Du J, et al. The application of the fibroblast activation protein α-targeted immunotherapy strategy. Oncotarget, 2016, 7(22): 33472-33482.
|
13. |
Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science, 2010, 330(6005): 827-830.
|
14. |
Jiang GM, Xie WY, Wang HS, et al. Curcumin combined with FAPαc vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-α in melanoma. Oncotarget, 2015, 6(28): 25932-25942.
|
15. |
Wikberg ML, Edin S, Lundberg IV, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol, 2013, 34(2): 1013-1020.
|
16. |
Iwasa S, Jin X, Okada K, et al. Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett, 2003, 199(1): 91-98.
|
17. |
Kawase T, Yasui Y, Nishina S, et al. Fibroblast activation protein-alpha-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. BMC Gastroenterol, 2015, 15: 109.
|
18. |
Wang H, Wu Q, Liu Z, et al. Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis, 2014, 5: e1155.
|
19. |
Ariga N, Sato E, Ohuchi N, et al. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer, 2001, 95(1): 67-72.
|
20. |
Ramirez-Montagut T, Blachere NE, Sviderskaya EV, et al. FAPα, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene, 2004, 23(32): 5435-5446.
|
21. |
Williams KH, Viera de Ribeiro AJ, Prakoso E, et al. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Res Clin Pract, 2015, 108(3): 466-472.
|
22. |
Rovedatti L, Di Sabatino A, Knowles CH, et al. Fibroblast activation protein expression in Crohn’s disease strictures. Inflamm Bowel Dis, 2011, 17(5): 1251-1253.
|
23. |
Wäldele S, Koers-Wunrau C, Beckmann D, et al. Deficiency of fibroblast activation protein alpha ameliorates cartilage destruction in inflammatory destructive arthritis. Arthritis Res Ther, 2015, 17: 12.
|
24. |
Brokopp CE, Schoenauer R, Richards P, et al. Fibroblast activation protein is induced by inflammation and degrades type Ⅰ collagen in thin-cap fibroatheromata. Eur Heart J, 2011, 32(21): 2713-2722.
|
25. |
Narra K, Mullins SR, Lee HO, et al. Phase Ⅱ trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther, 2007, 6(11): 1691-1699.
|
26. |
Eager RM, Cunningham CC, Senzer N, et al. Phase Ⅱ trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol), 2009, 21(6): 464-472.
|
27. |
Eager RM, Cunningham CC, Senzer NN, et al. Phase Ⅱ assessment of talabostat and cisplatin in second-line stage Ⅳ melanoma. BMC Cancer, 2009, 9: 263.
|
28. |
Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie, 2003, 26(1): 44-48.
|
29. |
Kloft C, Graefe EU, Tanswell P, et al. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs, 2004, 22(1): 39-52.
|
30. |
Ostermann E, Garin-Chesa P, Heider KH, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res, 2008, 14(14): 4584-4592.
|
31. |
Fischer E, Chaitanya K, Wüest T, et al. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res, 2012, 18(22): 6208-6218.
|
32. |
van der Geest T, Laverman P, Gerrits D, et al. Liposomal treatment of experimental arthritis can be monitored noninvasively with a radiolabeled anti-fibroblast activation protein antibody. J Nucl Med, 2017, 58(1): 151-155.
|
33. |
Xia Q, Zhang FF, Geng F, et al. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model. Cancer Immunol Immunother, 2016, 65(5): 613-624.
|
34. |
Xia Q, Geng F, Zhang FF, et al. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma. Immunopharmacol Immunotoxicol, 2017, 39(1): 37-44.
|
35. |
Wen Y, Wang CT, Ma TT, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci, 2010, 101(11): 2325-2332.
|
36. |
张莉, 陈扬扬, 祝先潮, 等. 一种靶向 FAP 的蛋白疫苗设计及其抗肿瘤保护研究. 安徽师范大学学报(自然科学版), 2014, 37(4): 366-370.0.
|
37. |
Gottschalk S, Yu F, Ji M, et al. A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. PLoS One, 2013, 8(12): e82658.
|
38. |
Brennen WN, Rosen DM, Wang H, et al. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst, 2012, 104(17): 1320-1334.
|
39. |
马伟峰, 杨飞华, 赵海山, 等. FAPα 酶激活式靶向抗肿瘤前药: Z-GP-Dox 对斑马鱼的毒性评价. 中国生物工程杂志, 2012, 32(7): 37-42.0.
|
40. |
Brennen WN, Rosen DM, Chaux A, et al. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. Prostate, 2014, 74(13): 1308-1319.
|